Notice of Annual General Meeting of Implantica AG
The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to…
5,335€
22,50%
Echtzeit-Aktienkurs IMPLANTICA AG SDR./1
Bid:
Ask:
Nachrichten zur IMPLANTICA AG SDR./1 Aktie
Bulletin from the Annual General Meeting of Implantica AG
Today, May 15, 2025, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Ruggell, Liechtenstein. The…
Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 23…
Implantica deepens market penetration in Italy with the addition of the ninth RefluxStop™ Center of Excellence and several lined up to start near-term
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device…
Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device…
Implantica announces highly successful 2024 American Foregut Society meeting where RefluxStop® received remarkable pre-launch market feedback
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, is pleased to report…
Implantica shares a landmark review article on standard of care Nissen Fundoplication anti-reflux surgery – in light of the recently announced excellent RefluxStop[TM] 5-year results
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device…
Implantica announces another landmark real-world RefluxStop™ study demonstrating excellent outcomes published in a prestigious top-tier journal
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces another key milestone…
Implantica announces excellent RefluxStop™ investigator initiated study results published in Scientific Reports, a Nature journal
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces the independent study…
Implantica announces new health-economics data publication showing RefluxStop™’s superior cost-effectiveness for the Swiss healthcare system
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, reports the study, “Analysis…
Bulletin from the Annual General Meeting of Implantica AG
Today, May 22, 2024, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Ruggel, Liechtenstein. The…
Implantica’s RefluxStop™ is now available in seven hospitals in Spain adding two new centers of excellence
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra. Beatriz…
Notice of Annual General Meeting of Implantica AG
The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to…
Implantica submits U.S. FDA Premarket Approval (PMA) application for RefluxStop® (first module)
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces the submission of…